The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with ...
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — In this Healio Video Perspective from ...
Direct anti-VEGF angiogenic agents were a strong risk factor for high-grade hypertension, and multikinase inhibitors for high-grade proteinuria. Vascular endothelial growth factor signaling pathway ...
Science Progress (1933-), Vol. 104, No. 3 (2021), pp. 1-14 (14 pages) Hepatocellular carcinoma is one of the leading causes of malignant tumor related death word wide with poor prognosis. Chemotherapy ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
Please provide your email address to receive an email when new articles are posted on . Bispecifics are a relatively new area in ophthalmology. In 2022, faricimab was the first-ever FDA-approved ...
Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases. Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback